<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7410019\results\search\testTrace\results.xml">
  <result pre="must be prepared for the possibility of substantial resurgences of" exact="infection" post="and adapt their approach to CLL management accordingly. In"/>
  <result pre="on incoming data from publications and the clinics in SARS-CoV-2" exact="infection" post="and related infectious conditions including other oncological diseases. Table"/>
  <result pre="We consider patients with CLL at increased risk of SARS-CoV-2" exact="infection" post="and COVID-19 morbidity and mortality due to their immune"/>
  <result pre="and fragility similar to patients with other malignancies Whether the" exact="prevalence" post="of COVID-19 in patients with cancer, including CLL, is"/>
  <result pre="of infection.19 We limit patientsâ€™ exposure to potential nosocomial SARS-CoV-2" exact="infection" post="by minimizing the number of visits, postponing in-hospital routine"/>
  <result pre="absence of a vaccine, the sole effective prevention of SARS-CoV-2" exact="infection" post="and COVID-19 is public health, non-pharmaceutical interventions aimed at"/>
  <result pre="Marrow aspirate and biopsy generally are not required for the" exact="diagnosis" post="of CLL.34 The staging of CLL does not use"/>
  <result pre="established, making it difficult to balance the risks of SARS-CoV-2" exact="infection" post="and those of starting, deferring, or halting treatment on"/>
  <result pre="of SARS-CoV-2 infection and those of starting, deferring, or halting" exact="treatment" post="on life expectancy. Nevertheless, under an epidemic scenario, we"/>
  <result pre="epidemic scenario, we estimate the risks of community and nosocomial" exact="infection" post="by SARS-CoV-2 and of complicated COVID-19 higher than the"/>
  <result pre="outbreak will become extinct),36 we estimate the benefit of a" exact="treatment" post="known to prolong the survival of patients with CLL"/>
  <result pre="with CLL higher than the risks of community and nosocomial" exact="infection" post="by SARS-CoV-2 and symptomatic COVID-19. This reasoning is based"/>
  <result pre="was reported for the Middle East respiratory syndrome as the" exact="infection" post="reproduction number declined toward a more endemic level (RÏ&quot;"/>
  <result pre="Third, the introduction of chemo(immuno)therapy and targeted agents in the" exact="treatment" post="of CLL led to a 6% relative survival improvement"/>
  <result pre="palliative therapies used in the 1980s.41,42 The decision about delivering" exact="treatment" post="should be primarily influenced by the tempo of SARS-CoV-2"/>
  <result pre="strongly consider the possibility of delaying the start of a" exact="treatment" post="even in advanced stage CLL. It is known that"/>
  <result pre="of cytopenia do not affect progression free survival of targeted" exact="treatment" post="of CLL,43â€&quot;61 and that cytopenias may remain stable over"/>
  <result pre="should be carefully evaluated on an individualized basis. In both" exact="treatment" post="naÃ¯ve and relapsed CLL, bulky lymphadenopathy occurs in only"/>
  <result pre="40% of cases and must be considered in the differential" exact="diagnosis" post="of anemia.62,63 Decreased hemoglobin for autoimmune hemolytic anemia can"/>
  <result pre="is not known whether corticosteroids increases the risk of SARS-CoV-2" exact="infection" post="or mitigates its severity.29,64â€&quot;70 Clinical trials with novel agents"/>
  <result pre="novel agents excluded patients with uncontrolled autoimmune hemolytic anemia.43â€&quot;46,54,56,58,59 However," exact="treatment" post="with BTK inhibitors facilitate withdrawal of ongoing immune suppressive"/>
  <result pre="can sometimes show improvement of systemic symptoms or LDT. When" exact="treatment" post="cannot be further deferred, we use the systemic therapy"/>
  <result pre="the recommendation is to reduce the risk of nosocomial SARS-CoV-2" exact="infection" post="by reducing hospital visits and to avoid chemo(immuno)therapy, idelalisib"/>
  <result pre="monoclonal antibodies with venetoclax until later in the course of" exact="treatment" post="when safer. Ibrutinib, acalabrutinib, and venetoclax prolong progression-free and"/>
  <result pre="for tumor lysis management during the ramp up phase. Ibrutinib" exact="treatment" post="requires few routine treatment visits and lab assessments.54 It"/>
  <result pre="during the ramp up phase. Ibrutinib treatment requires few routine" exact="treatment" post="visits and lab assessments.54 It is associated with a"/>
  <result pre="the immune reconstitution of T-cells, which in turns decreases the" exact="infection" post="rate after the first 6 months of therapy.54,80,84,85 BTK"/>
  <result pre="few reports from uncontrolled clinical cases.86,87 The disadvantage of ibrutinib" exact="treatment" post="during SARS-CoV-2 outbreak is the continuous schedule not allowing"/>
  <result pre="treatment during SARS-CoV-2 outbreak is the continuous schedule not allowing" exact="treatment" post="free intervals. However, if ibrutinib is discontinued because of"/>
  <result pre="of 60 days from venetoclax discontinuation.83,91 The disadvantage of venetoclax" exact="treatment" post="is the need for frequent access to the hospital"/>
  <result pre="phase to prevent tumor lysis syndrome (TLS).58 In addition, venetoclax" exact="treatment" post="has a relatively high risk of neutropenia during the"/>
  <result pre="of B-lymphocytes that may persist for a long time after" exact="treatment" post="discontinuation.94 Rituximab therapy may facilitate JC and hepatitis B"/>
  <result pre="therapy during the pandemic We test asymptomatic patients for SARS-CoV-2" exact="infection" post="by nasopharyngeal swab RT-PCR 72-24â€Šhours before starting CLL therapy."/>
  <result pre="respiratory tract symptoms.104â€&quot;106 The specificity of such symptoms toward COVID-19" exact="diagnosis" post="is decreased because they may overlap with common adverse"/>
  <result pre="of patients with COVID-19 have superinfections.9,111â€&quot;113 Management of patients on" exact="treatment" post="for CLL lacking evidence of COVID-19 We continue treatment"/>
  <result pre="on treatment for CLL lacking evidence of COVID-19 We continue" exact="treatment" post="with targeted agents in patients lacking COVID-19 symptoms as"/>
  <result pre="ibrutinib, acalabrutinib or venetoclax based on the reasoning that once" exact="treatment" post="has started, the dose intensity should be preserved to"/>
  <result pre="suggesting that patients who are able to better adhere to" exact="treatment" post="may derive more benefit.46,58,90,114â€&quot;119 In patients already receiving prophylactic"/>
  <result pre="product, but can help in preventing additional infections. Bacterial secondary" exact="infection" post="can complicate viral infections, a situation well known in"/>
  <result pre="in COVID-19.120,121 Immunoglobulin replacement therapy reduces the risk of major" exact="infection" post="in patients with CLL and low serum IgG.122 Subcutaneous"/>
  <result pre="institutions, anti-meningococcal vaccination is also included. Management of patients on" exact="treatment" post="for CLL who receive a COVID-19 diagnosis In patients"/>
  <result pre="of patients on treatment for CLL who receive a COVID-19" exact="diagnosis" post="In patients on treatment for CLL, who receive a"/>
  <result pre="for CLL who receive a COVID-19 diagnosis In patients on" exact="treatment" post="for CLL, who receive a COVID-19 diagnosis, holding therapy"/>
  <result pre="receive a COVID-19 diagnosis, holding therapy until the recovery from" exact="infection" post="is a prudent approach Patients with CLL may be"/>
  <result pre="effective at treating severe COVID-19. Use of investigational therapies for" exact="treatment" post="of patients with CLL and with COVID-19 should ideally"/>
  <result pre="with CLL must be prepared for possible outbreaks of the" exact="infection" post="and adapt the management of patients with CLL accordingly,"/>
  <result pre="for further refinement as our understanding of SARS-CoV-2 and COVID-19" exact="infection" post="unfolds, a process which requires a continued multidisciplinary and"/>
  <result pre="2019. J Clin Invest.2020;130:2620â€&quot;2629.32217835 13.RussellCDMillarJEBaillieJKClinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injury. Lancet.2020;395:473â€&quot;475.32043983 14.Wu Z, McGoogan JM."/>
  <result pre="(SIOG) Task Force. Ann Oncol.2017;28:218â€&quot;227.27803007 18.GoedeVCramerPBuschRet al.Interactions between comorbidity and" exact="treatment" post="of chronic lymphocytic leukemia: results of German Chronic Lymphocytic"/>
  <result pre="Nat Med.2020;26:665â€&quot;671.32405058 38.HannaTPEvansGABoothCMet al.Cancer, COVID-19 and the precautionary principle: prioritizing" exact="treatment" post="during a global pandemic. Nat Rev Clin Oncol.2020;17:268â€&quot;270.32242095 39.DignaniMCCostantiniPSalgueiraCet"/>
  <result pre="Rev Clin Oncol.2020;17:268â€&quot;270.32242095 39.DignaniMCCostantiniPSalgueiraCet al.Pandemic 2009 Influenza A (H1N1) virus" exact="infection" post="in cancer and hematopoietic stem cell transplant recipients; a"/>
  <result pre="45.MorenoCGreilRDemirkanFet al.Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line" exact="treatment" post="of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label,"/>
  <result pre="phase 3 trial of ibrutinib vs ofatumumab. Blood.2019;133:2031â€&quot;2042.30842083 50.ByrdJCFurmanRRCoutreSEet al.Ibrutinib" exact="treatment" post="for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis"/>
  <result pre="J Hematol.2019;94:1353â€&quot;1363.31512258 54.BurgerJABarrPMRobakTet al.Long-term efficacy and safety of first-line ibrutinib" exact="treatment" post="for patients with CLL/SLL: 5 years of follow-up from"/>
  <result pre="undergoing chemotherapy. Med Oncol.2014;31:302.25373320 64.AuyeungTWLeeJSLaiWKet al.The use of corticosteroid as" exact="treatment" post="in SARS was associated with adverse outcomes: a retrospective"/>
  <result pre="for thrombosis and anticoagulation. Blood.2020;135:2033â€&quot;2040.32339221 78.MozasPRivas-DelgadoABaumannTet al.Analysis of criteria for" exact="treatment" post="initiation in patients with progressive chronic lymphocytic leukemia. Blood"/>
  <result pre="ibrutinib. Blood.2015;126:2213â€&quot;2219.26337493 81.VarugheseTTaurYCohenNet al.Serious infections in patients receiving ibrutinib for" exact="treatment" post="of lymphoid cancer. Clin Infect Dis.2018;67:687â€&quot;692.29509845 82.RogersKAMousaLZhaoQet al.Incidence of"/>
  <result pre="Clin Infect Dis.2018;67:687â€&quot;692.29509845 82.RogersKAMousaLZhaoQet al.Incidence of opportunistic infections during ibrutinib" exact="treatment" post="for B-cell malignancies. Leukemia.2019;33:2527â€&quot;2530.31086260 83.de WeerdtIHoflandTde BoerRet al.Distinct immune"/>
  <result pre="patients is reshaped during venetoclax treatment. Blood Adv.2019;3:2642â€&quot;2652.31506282 84.LongMBeckwithKDoPet al.Ibrutinib" exact="treatment" post="improves T cell number and function in CLL patients."/>
  <result pre="relapsed indolent lymphoma: half of patients respond to a four-dose" exact="treatment" post="program. J Clin Oncol.1998;16:2825â€&quot;2833.9704735 95.CarsonKRFocosiDMajorEOet al.Monoclonal antibody-associated progressive multifocal"/>
  <result pre="multinational consensus statement from the Fleischner society. Chest.2020;158:106â€&quot;116.32275978 104.ChowEJSchwartzNGTobolowskyFAet al.Symptom" exact="screening" post="at illness onset of health care personnel with SARS-CoV-2"/>
  <result pre="screening at illness onset of health care personnel with SARS-CoV-2" exact="infection" post="in King County, Washington. JAMA.2020;323:2087â€&quot;2089. 105.CheungKSHungIFChanPPet al.Gastrointestinal manifestations of"/>
  <result pre="in King County, Washington. JAMA.2020;323:2087â€&quot;2089. 105.CheungKSHungIFChanPPet al.Gastrointestinal manifestations of SARS-CoV-2" exact="infection" post="and virus load in fecal samples from the Hong"/>
  <result pre="print]. 106.BenezitFLe TurnierPDeclerckCet al.Utility of hyposmia and hypogeusia for the" exact="diagnosis" post="of COVID-19. Lancet Infect Dis.2020;April 15. [Epub ahead of"/>
  <result pre="a skilled nursing facility. N Engl J Med.2020;382:2081â€&quot;2090.32329971 109.KongWHLiYPengMWet al.SARS-CoV-2" exact="detection" post="in patients with influenza-like illness. Nat Microbiol.2020;5:675â€&quot;678.32265517 110.BordiLNicastriEScorzoliniLet al.Differential"/>
  <result pre="detection in patients with influenza-like illness. Nat Microbiol.2020;5:675â€&quot;678.32265517 110.BordiLNicastriEScorzoliniLet al.Differential" exact="diagnosis" post="of illness in patients under investigation for the novel"/>
  <result pre="novel coronavirus (SARS-CoV-2), Italy, February 2020. Euro Surveill.2020;25:2000170. 111.ChuHYEnglundJAStaritaLMet al.Early" exact="detection" post="of Covid-19 through a citywide pandemic surveillance platform. N"/>
  <result pre="115.ThompsonPAPetersonCBStratiPet al.Serial minimal residual disease (MRD) monitoring during first-line FCR" exact="treatment" post="for CLL may direct individualized therapeutic strategies. Leukemia.2018;32:2388â€&quot;2398.29769624 116.BurgerJATedeschiABarrPMet"/>
  <result pre="Med.2015;373:2425â€&quot;2437.26639149 117.World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected. 2020, March 13. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed"/>
  <result pre="print]. 119.BhimrajAMorganRLShumakerAHet al.Infectious diseases society of america guidelines on the" exact="treatment" post="and management of patients with COVID-19. Clin Infect Dis.2020;April"/>
  <result pre="with coronavirus disease 2019 (COVID-19). Crit Care Med.2020;48:e440â€&quot;e469.32224769 125.YuFYanLWangNet al.Quantitative" exact="detection" post="and viral load analysis of SARS-CoV-2 in infected patients."/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect Dis.2020;20:565â€&quot;574.32213337"/>
 </snippets>
</snippetsTree>
